Q3 FY2026 · ended Oct 2, 2026 · Revenue $83.41M, -12.0% YoY · Filed Nov 4, 2026
STAAR Surgical Co (STAA) files with the SEC under industry code 3851, Ophthalmic Goods. In Q3 of fiscal 2026, the quarter ended Oct 2, 2026, it reported revenue of $83.4 million and net income of $5.6 million. Free cash flow was $26.4 million. As of Oct 2, 2026 it held $206.4 million in cash and investments and $33.6 million in total debt.
Revenue
$83.41M
-12.0% vs year-ago quarter
Net income
$5.58M
-37.2% vs year-ago quarter
Operating cash flow
$27.32M
+924.2% vs year-ago quarter
Free cash flow
$26.38M
+1378.7% vs year-ago quarter
EPS
$0.11
-38.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
50.20M
+0.9% vs year-ago quarter
Net cash
$172.77M
Q3 FY2026
Operating margin
0.2%
TTM
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- STAA (Nasdaq)
- Fiscal year ends
- January 2
- Incorporated in
- DE
- Headquarters
- Monrovia, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 718937
- Former names
- STAAR SURGICAL COMPANY (until Aug 17, 2004)
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Bausch & Lomb Corp BLCO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- RxSight, Inc. RXST
- Innovative Eyewear Inc LUCY
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Oct 2, 2026 |
Q2 FY2026 Jul 3, 2026 |
Q1 FY2026 Apr 3, 2026 |
Q4 FY2025 Jan 2, 2026 |
Q3 FY2025 Sep 26, 2025 |
|---|---|---|---|---|---|
| Revenue | $83.4M | $93.5M | $93.5M | $57.8M | $94.7M |
| Operating income | $5.5M | $10.1M | $8.0M | -$22.8M | $18.5M |
| Net income | $5.6M | $8.1M | $5.2M | -$18.3M | $8.9M |
| Diluted EPS | $0.11 | $0.16 | $0.10 | -$0.37 | $0.18 |
| Operating cash flow | $27.3M | $19.7M | -$21.7M | -$3.9M | $2.7M |
| Free cash flow | $26.4M | $19.2M | -$22.1M | -$5.6M | $1.8M |
| Total assets | $485.2M | $475.2M | $451.1M | $451.7M | $456.4M |
| Total liabilities | $109.0M | $109.8M | $98.8M | $107.5M | $102.6M |
| Stockholders' equity | $376.1M | $365.4M | $352.4M | $344.2M | $353.8M |
| Cash and investments | $206.4M | $181.5M | $163.9M | $187.5M | $192.7M |
| Total debt | $33.6M | $35.9M | $37.3M | $38.4M | $39.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Oct 5, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
All 1001 STAAR Surgical Co SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.